Clinical trial • Phase II • Cardiology

ESKETAMINE HYDROCHLORIDE for Out-of-hospital cardiac arrest

Phase II trial of ESKETAMINE HYDROCHLORIDE for Out-of-hospital cardiac arrest.

Overview

Trial Therapeutic Area
Cardiology
Trial Disease
Out-of-hospital cardiac arrest
Trial Stage
Phase II
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
25-07-2024
First CTIS Authorization Date
01-10-2024

Trial design

Randomised, propolipid (propofol) — emulsion for injection/infusion; max total dose 6 mg/kg (doseuom: mg/kg); route: intravenous bolus injection/iv infusion.-controlled Phase II trial across 2 sites in Denmark.

Randomised
Yes
Comparator
Propolipid (propofol) — EMULSION FOR INJECTION/INFUSION; max total dose 6 mg/kg (doseUom: mg/kg); route: INTRAVENOUS BOLUS INJECTION/IV INFUSION.
Target Sample Size
282
Trial Duration For Participant
180

Eligibility

Recruits 282 Vulnerable population selected. Subject information and informed consent forms are provided for subject, trial guardian, next of kin, and death next of kin, indicating consent/permission processes via trial guardian or next of kin for incapacitated participants..

Pregnancy Exclusion
Woman of childbearing capacity (female aged 18-40, decided by the treating physician if no information is available)
Vulnerable Population
Vulnerable population selected. Subject information and informed consent forms are provided for subject, trial guardian, next of kin, and death next of kin, indicating consent/permission processes via trial guardian or next of kin for incapacitated participants.

Inclusion criteria

  • {"criterion_text":"- 1.\tAge ≥18 years (presumed if not known)\n- 2.\tOHCA of presumed cardiac cause. *\n- 3.\tPrimary shockable rhythm (ventricular fibrillation or pulseless ventricular tachycardia) **\n- 4.\tDecision to perform prehospital intubation after resuscitation (as decided by treating physician) or intubated during CPR with additional need for sedation.\n- 5.\tAdministration of study medicine injection before hospital arrival is considered feasible.\n- 6.\tROSC with MAP ≥40 mmHg *i.e. admission to Rigshospitalet or Odense University Hospital: national guidelines state that all OHCA patients with presumed cardiac arrest must be referred to the two main hospitals in the respective regions — Rigshospitalet for all OHCA cases in Region Zealand and the Capital Region, and Odense University Hospital for all OHCA cases in Region South. **If a defibrillator shock by an automated external defibrillator is delivered or advised before arrival of the EMS, it is considered a “primary shockable rhythm.”"}

Exclusion criteria

  • {"criterion_text":"- 1.\tAdvanced life support TOR exclusion criteria fulfilled\n- 2.\tRefractory cardiac arrest transferred for extracorporeal membrane oxygenation\n- 3.\tWoman of childbearing capacity (female aged 18-40, decided by the treating physician if no information is available)\n- 4.\tKnown therapy limitation (known decision made of no resuscitation or intensive therapy)\n- 5.\tKnown allergy to ketamine or propofol\n- 6.\tSystolic blood pressure >190 mmHg\n- 7.\tKnown chronic disease making 180-day survival unlikely\n- 8.\tKnown pre-arrest mRS score of ≤5\n- 9.\tNursing home resident\n- 10.\tTemperature upon admission <30° C"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Neuron-specific enolase (NSE) measured 48 hours after OHCA","definition_or_measurement_approach":"NSE biomarker measured 48 hours after out-of-hospital cardiac arrest (measurement timepoint specified as 48 hours)."}

Secondary endpoints

  • {"endpoint_text":"- Death from all causes at 180 days after cardiac arrest.\n- CPC- and mRS score at hospital discharge and 180-240 days after cardiac arrest.","definition_or_measurement_approach":"Death from all causes assessed at 180 days post-arrest. Cerebral Performance Category (CPC) and modified Rankin Scale (mRS) scores assessed at hospital discharge and at 180-240 days after cardiac arrest."}

Recruitment

Planned Sample Size
282
Recruitment Window Months
36
Consent Approach
Informed consent/permission materials exist for subjects, trial guardians, next of kin, and death next of kin (documents listed: subject ICF, trial guardian ICF, next of kin ICF, death next of kin ICF). As the population are adults after OHCA and many will be incapacitated on enrollment, consent appears to be handled via trial guardian/next of kin documents. Languages of consent documents are not specified in the available record.

Geography

Total Number Of Sites
2
Total Number Of Participants
282

Denmark

Earliest CTIS Part Ii Submission Date
27-09-2024
Latest Decision Or Authorization Date
01-10-2024
Processing Time Days
4
Number Of Sites
2
Number Of Participants
282

Sites

Site Name
Rigshospitalet
Department Name
Department of Cardiology
Principal Investigator Name
Christian Hassager
Principal Investigator Email
christian.hassager@regionh.dk
Contact Person Name
Christian Hassager
Contact Person Email
christian.hassager@regionh.dk
Site Name
Odense University Hospital
Department Name
Department of Cardiothoracic Anesthesiology
Principal Investigator Name
Henrik Schmidt
Principal Investigator Email
henrik.schmidt@rsyd.dk
Contact Person Name
Henrik Schmidt
Contact Person Email
henrik.schmidt@rsyd.dk

Sponsor

Primary sponsor

Full Name
Rigshospitalet
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Denmark

Third parties

  • {"country":"Denmark","full_name":"Frederiksberg Hospital","duties_or_roles":"[{\"id\":593667,\"code\":\"1\"}]","organisation_type":"Hospital/Clinic/Other health care facility"}

Investigational products

Investigational Product Name
S-ketamin "Pfizer" injektionsvæske, opløsning
Active Substance
ESKETAMINE HYDROCHLORIDE
Modality
Small molecule
Routes Of Administration
INTRAVENOUS BOLUS INJECTION/IV INFUSION
Route
INTRAVENOUS BOLUS INJECTION/IV INFUSION
Authorisation Status
Authorised (marketing authorisation number 19569 in DK)
Maximum Dose
4 mg/kg
Investigational Product Name
Propolipid
Active Substance
PROPOFOL
Modality
Small molecule
Routes Of Administration
INTRAVENOUS BOLUS INJECTION/IV INFUSION
Route
INTRAVENOUS BOLUS INJECTION/IV INFUSION
Authorisation Status
Authorised (marketing authorisation number 49586; MRP DE/H/0490/003 referenced)
Maximum Dose
6 mg/kg

Related trials

Other published trials that may interest you.